Nonpatentable drugs and the cost of our ignorance
Open Access
- 13 February 2006
- journal article
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 174 (4), 483-484
- https://doi.org/10.1503/cmaj.050663
Abstract
The pharmaceutical industry spends over US$10 billion to fund some 90% of the 40 000–80 000 randomized controlled clinical trials (RCTs) being conducted across the world at any given time.[1][1],[2][2],[3][3] By its own estimation, the pharmaceutical industry in Canada spent Can$501.8 million onThis publication has 20 references indexed in Scilit:
- The high prevalence of inadequate serum vitamin D levels and implications for bone healthCurrent Medical Research and Opinion, 2005
- A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse ModelJournal of Neuroscience, 2005
- Registering CIHR-funded randomized controlled trials: a global public goodCMAJ : Canadian Medical Association Journal, 2004
- Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse ModelNeuron, 2004
- Vitamin D and Calcium Supplementation Prevents Osteoporotic Fractures in Elderly Community Dwelling Residents: A Pragmatic Population-Based 3-Year Intervention StudyJournal of Bone and Mineral Research, 2004
- Biological Safety Assessment of Docosahexaenoic Acid Supplementation in a Randomized Clinical Trial for X-Linked Retinitis PigmentosaAmerican Journal of Ophthalmology, 2003
- Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case–control studyBritish Journal of Nutrition, 2003
- Some Practical Guidelines for Effective Sample Size DeterminationThe American Statistician, 2001
- n−3 fatty acids and human health: Defining strategies for public policyLipids, 2001
- Low serum docosahexaenoic acid is a significant risk factor for alzheimer's dementiaLipids, 1999